TheraRadar
← Back
Data updated: Jun 28, 2026

GEN HOSP

Generics
Pharmaceuticals

GEN HOSP is a generic drug manufacturer with 1 FDA-approved products.

2016
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
Oct 9, 2026 — Tecentriq (atezolizumab) + chemotherapy
+2 more dates (Pro)

GEN HOSP's Key Drugs

GEN HOSP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

GEN HOSP's Recent FDA Approvals

New NDA/BLA approvals for GEN HOSP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

GEN HOSP's Therapeutic Areas

Disease areas where GEN HOSP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

GEN HOSP Pipeline Snapshot

Active clinical trials for GEN HOSP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling